---
document_datetime: 2025-10-06 14:50:44
document_pages: 13
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/nuvaxovid-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: nuvaxovid-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.9387625
conversion_datetime: 2025-12-28 01:39:49.196492
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Nuvaxovid

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number      | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|-------------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Marketing Authorisation | - Transfer of a marketing authorisation - | 11/09/2025                          | 01/10/2025                                  | SmPC,                            |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| Transfer - H / EMA/T/0000292057       | transfer of marketing authorization from Novavax CZ a.s. to Sanofi Winthrop Industrie                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            | Labelling and PL       |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| Variation type IB / EMA/VR/0000287007 | This was an application for a group of variations. B.IV.1.a Addition or replacement of a device which is not an integrated part of the primary packaging - B.IV.1.a.1 Device with CE marking - Accepted B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.2 Change outside the range of the currently approved pack sizes - Accepted B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.2 Change outside the range of the currently approved pack sizes - Accepted | 27/08/2025 | 01/10/2025 | SmPC, Labelling and PL |
| Variation type IB / EMA/VR/0000280145 | This was an application for a group of variations. B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.z Other changes - Accepted                                                                                                                                                                                                                                                                                                                                                               | 06/08/2025 | N/A        |                        |

<div style=\"page-break-after: always\"></div>

|                                       | B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted                                                                                                                                 |            |     |                   |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| Variation type II /                   | B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.b Replacement or addition of a site where batch control/testing takes place for a biological/immunological product and any of the test methods performed at the site is a biological/immunological method - Accepted       | 24/07/2025 | N/A | EMA/VR/0000279400 |
| Variation type IB / EMA/VR/0000281689 | B.II.f) Stability - B.II.f.z Other variation - Accepted                                                                                                                                                                                                                                                                                           | 15/07/2025 | N/A |                   |
| Variation type IB / EMA/VR/0000280839 | This was an application for a group of variations. B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted B.I.c.1 Change in immediate packaging of the active substance - B.I.c.1.a Qualitative and/or quantitative composition - Accepted | 10/07/2025 | N/A |                   |

<div style=\"page-break-after: always\"></div>

|                                       | B.I.c) Container closure system - B.I.c.z Change of a secondary packaging component of the drug substance (including replacement or addition) - Accepted                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |      |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|
| Variation type IB / EMA/VR/0000276489 | B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 08/07/2025 | N/A        |      |
| Variation type IB / EMA/VR/0000275733 | B.I ACTIVE SUBSTANCE - B.I.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 02/07/2025 | N/A        |      |
| Variation type II / EMA/VR/0000257341 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.8 and 5.1 of the SmPC in order to update clinical efficacy and safety information, based on data from the previously submitted final CSRs for studies 2019nCoV-101 Part 2, 2019nCoV-501, 2019nCoV-301 (Adult population) and 2019nCoV-302. In addition, the MAH took the opportunity to introduce minor changes to the PI. | 26/06/2025 | 01/10/2025 | SmPC |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000275734   | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Other variation - Accepted C.I.z (IB) - To formally incorporate presentation EU/1/21/1618/011 within the approved variations: EMEA/H/C/00508/II/0083 EMEA/H/C/005808/II/0084 EMEA/H/C/005808/II/0087 EMEA/H/C/005808/II/0090 EMEA/H/C/005808/II/0093 EMEA/H/C/005808/II/0097/G EMA/VR/0000256540                                                                                                                                                                 | 26/06/2025   | N/A   |
|-----------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| Variation type II / EMA/VR/0000257347   | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.b Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment by the competent authority is required* - Accepted Submission of an updated RMP version 7.1 in order to align with the latest information in the SmPC, recently completed clinical study reports, and PSUR. | 05/06/2025   | N/A   |
| Variation type IB / EMA/VR/0000266386   | B.II.f) Stability - B.II.f.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 28/05/2025   | N/A   |

<div style=\"page-break-after: always\"></div>

| Variation type II / EMA/VR/0000256540   | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.13 Submission of additional clinical and non-clinical studies, including BE-studies. - Accepted Submission of the interim clinical study report 2019nCoV-315 Day 28; this is a Phase 3 Open-Label, Single-Arm Study to Evaluate the Safety and Immunogenicity of a JN.1 Subvariant SARS-CoV-2 rS Vaccine (Nuvaxovid JN.1).                                                                                                                                                                                                                                                                | 15/05/2025   | N/A   |
|-----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| Variation type II / EMA/VR/0000245258   | This was an application for a group of variations. B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.j Changes to quality control testing arrangements for a biological active substance: replacement or addition of a site where batch control/testing including a biological / immunological / immunochemical method takes place - Accepted | 08/05/2025   | N/A   |

<div style=\"page-break-after: always\"></div>

|                                       | starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.j Changes to quality control testing arrangements for a biological active substance: replacement or addition of a site where batch control/testing including a biological / immunological / immunochemical method takes place - Accepted   |            |            |                 |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|
| Variation type II / EMA/VR/0000245100 | B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.b Replacement or addition of a site where batch control/testing takes place for a biological/immunological product and any of the test methods performed at the site is a biological/immunological method - Accepted                                                                                                                                                                                                        | 08/05/2025 | N/A        |                 |
| Variation type IB / EMA/VR/0000264389 | This was an application for a group of variations. A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for                                                                                                                                                                                                                                                                                                                         | 30/04/2025 | 01/10/2025 | Annex II and PL |

<div style=\"page-break-after: always\"></div>

| batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted  A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.a The activities for which the manufacturer/importer is responsible include batch release - Accepted  A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted  A.7 (Type IA) - To delete Novavax CZ a.s., Bohumil 138, 281 63 Jevany, Czech Republic as a site responsible for manufacturing of the active substances SARS-CoV-2 rS JN.1, SARS-CoV-2 rS XBB.1.5 and SARS-CoV-2 rS. A.4 (Type IB) - To change the name of the site responsible for stability testing of the   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | active substance SARS-CoV-2 rS JN.1 from Novavax CZ a.s., Bohumil 138, 281 63 Jevany, Czech Republic to Novo Nordisk Production Czech s.r.o. Bohumil 138, 281 63 Jevany, Czech Republic. The address remains unchanged. A.5.a (Type IB) - To change the name of the site responsible for Batch Release and Stability Quality Control testing of the finished product from Novavax CZ a.s., Bohumil 138, 281 63 Jevany, Czech Republic to Novo Nordisk Production Czech s.r.o. Bohumil 138, 281 63 Jevany, Czech Republic. In addition, the marketing authorisation holder has taken the opportunity to update section 3.2.P.3.1 as editorial change to delete footnote related to sterility testing at Manjari site and to implement minor editorial change in Section 6 of the PL to move around the manufacturing site Novamax CZ a.s, Libalova 2348/1, Chodov, 149 00 Praha 4,   |            |     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000262069 | B.I.d.1.a Re-test period/storage period - B.I.d.1.a.4 Extension or introduction of a re- test period/storage period supported by real time data - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 24/04/2025 | N/A |
| Variation type IB / EMA/VR/0000255800 | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 03/04/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.z Other variation - Accepted B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.a The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer - Accepted   |            |     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000256070 | This was an application for a group of variations. B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.c Other changes to a test procedure (including replacement or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 31/03/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | a significant effect on the overall quality of the active substance - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.c Other changes to a test procedure (including replacement or addition) for a reagent, which does not have a significant effect on the overall quality of the active substance - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.c Other changes to a test procedure (including replacement or addition) for a reagent, which does not have a significant effect on the overall quality of   |            |     |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000249663 | This was an application for a group of variations. B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted B.I ACTIVE SUBSTANCE - B.I.z Other                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 13/03/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |     |                   |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| Variation type IB /                   | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Other variation - Accepted C.I.z (IB) - To formally incorporate presentation EU/1/21/1618/005 within the listed variations: - EMEA/H/C/00508/II/0062 - EMEA/H/C/005808/II/0066 - EMEA/H/C/005808/II/0069 - PSUSA/00010972/202312                                                                                                                                                                                                                                                                                                           | 12/03/2025 | N/A | EMA/VR/0000249662 |
| Variation type IB / EMA/VR/0000247776 | This was an application for a group of variations. B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.b Tightening of specification limits - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.b Tightening of specification limits - Accepted B.I.b.1 Change in the specification | 07/03/2025 | N/A |                   |

<div style=\"page-break-after: always\"></div>

|                                  | substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.b Tightening of specification limits - Accepted   |            |            |    |
|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|
| Article 61(3) / EMA/N/0000245170 | - - Accepted Update of the package leaflet with the addition of contact details of local representatives.                                                                   | 11/02/2025 | 01/10/2025 | PL |
| PSUR / EMA/PSUR/0000257887       | - -                                                                                                                                                                         |            |            |    |